GlassScriptPhysician profile
Amelia R Williams
NPI 1215162268
$3,521.12
in general payments reported to CMS, 2019-2025
28 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $796 · 2022: $668 · 2023: $825 · 2024: $725 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $740.36 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $643.99 | 2021-2025 | |
| Mylan Specialty L.P. | $455.75 | 2021-2024 | Yupelri |
| Amgen INC. | $366.55 | 2021-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $227.46 | 2022-2025 | Trintellix |
| Glaxosmithkline, LLC. | $122.20 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.73 | 2021-2024 | Xifaxan |
| Exact Sciences Corporation | $119.23 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $105.40 | 2022-2024 | Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $59.07 | 2021-2022 | |
| Axsome Therapeutics, INC. | $58.15 | 2025 | Auvelity |
| Novo Nordisk INC | $51.64 | 2021-2024 | Ozempic |
| Corcept Therapeutics | $39.64 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $38.21 | 2023 | Gemtesa |
| Astellas Pharma US INC | $38.17 | 2023 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $36.55 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $35.20 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $33.56 | 2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $32.45 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.07 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $28.05 | 2021-2022 | |
| Boston Scientific Corporation | $26.97 | 2025 | Wavewriter Alpha Prime 16 |
| Dexcom, INC. | $25.47 | 2025 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $20.22 | 2021 | |
| Genzyme Corporation | $19.61 | 2024 | |
| Merck Sharp & Dohme LLC | $16.68 | 2022 | |
| Esperion Therapeutics, INC. | $16.16 | 2025 | Nexletol |
| Currax Pharmaceuticals LLC | $13.58 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.